Amphetamine-Dextroamphetamine
Indications
| Indication | Approved Population | Formulation | Status |
|---|---|---|---|
| Attention-Deficit/Hyperactivity Disorder (ADHD) | Adderall (IR): pediatric ≥3 years and adults Adderall XR: pediatric ≥6 years and adults | IR tablet and XR capsule | FDA Approved |
| Narcolepsy | Adults and pediatric ≥6 years | Adderall IR tablet only (Adderall XR is NOT approved for narcolepsy) | FDA Approved (IR only) |
Mixed amphetamine salts are one of the two principal first-line stimulant treatment options for ADHD, alongside methylphenidate-class agents. Network meta-analysis evidence (Cortese et al., 2018) suggests amphetamine-class stimulants have a modestly greater efficacy in adult ADHD on average, while methylphenidate is generally favoured first in pediatric populations on tolerability grounds. The choice between them is largely empirical, and a substantial minority of patients respond preferentially to one class but not the other.
Adderall XR is approved for ADHD only — it does not carry the narcolepsy indication. For narcolepsy, the immediate-release Adderall tablet is the appropriate amphetamine product. Modafinil and armodafinil are non-Schedule II alternatives that are commonly preferred first-line for narcolepsy in adults.
Treatment-resistant depression (augmentation): Used at low doses in geriatric and palliative psychiatry where rapid mood and energy improvement are needed; evidence quality low.
Cancer-related fatigue and depression in palliative care: Short-term low-dose use to improve fatigue, attention, and depressive symptoms in advanced illness; evidence quality low to moderate.
Cognitive symptoms in traumatic brain injury and post-stroke recovery: Some use in rehabilitation settings for attention and processing speed, although methylphenidate has more rehabilitation literature; evidence quality low.
Binge eating disorder (related compound): The pure d-amphetamine prodrug lisdexamfetamine (Vyvanse) is FDA-approved for binge eating disorder in adults; mixed amphetamine salts are not approved for this indication and are not interchangeable.
Off-label use as a “study aid” or cognitive enhancer in non-ADHD individuals is not supported by clinical evidence and is associated with substantial misuse risk; this practice should be actively discouraged.
Dosing
Mixed amphetamine salts are available as immediate-release tablets (Adderall) and extended-release capsules (Adderall XR). The two products contain the same active mixture but differ in delivery: IR tablets typically cover 4–6 hours and require 1–2 daily doses; XR capsules cover 10–12 hours with once-daily morning dosing. Based on bioequivalence data, divided IR doses (e.g., twice daily) can be switched to the same total daily dose of XR taken once daily, then re-titrated for tolerability. Dosing is individualised — administer at the lowest effective dose. Late evening doses must be avoided because of insomnia risk.
ADHD — by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| ADHD — pediatric (3–5 y), Adderall IR | 2.5 mg PO once daily (morning) | Titrate weekly by 2.5 mg until optimal response | Not formally specified; individualise | Not recommended <3 years First dose on awakening; avoid late dosing |
| ADHD — pediatric (≥6 y), Adderall IR | 5 mg PO once or twice daily | Titrate weekly by 5 mg increments to optimal response | 40 mg/day (rarely needed to exceed) | Additional doses 4–6 hours apart First dose on awakening |
| ADHD — pediatric (6–12 y), Adderall XR | 10 mg PO once daily (morning); 5 mg if lower start indicated | Titrate weekly by 5 or 10 mg increments | 30 mg/day (doses >30 mg not studied in this group) | Swallow capsule whole or sprinkle contents on applesauce — do not chew Take in morning; avoid afternoon doses |
| ADHD — adolescent (13–17 y), Adderall XR | 10 mg PO once daily (morning) | May increase to 20 mg/day after 1 week if symptoms not adequately controlled | Higher doses individualised per response and tolerability | Same administration rules as pediatric |
| ADHD — adult, Adderall XR | 20 mg PO once daily (morning) | Adjust by tolerability and response | Higher doses individualised per response and tolerability | Whole capsule or sprinkle on applesauce; consume immediately |
| ADHD — switching IR to XR | Same total daily dose taken once daily as XR (per bioequivalence data); re-titrate weekly | Most patients tolerate the conversion well Confirm “dispense as written” on prescriptions | ||
| ADHD — Adderall XR, severe renal impairment (GFR 15 to <30 mL/min/1.73 m²), pediatric (6–17 y) | 5 mg PO once daily | Titrate based on response and tolerability | 20 mg/day (children 6–12 y with renal impairment) | Reduced dose required due to reduced clearance |
| ADHD — Adderall XR, severe renal impairment (GFR 15 to <30 mL/min/1.73 m²), adult | 15 mg PO once daily | Titrate based on response and tolerability | Lower than standard adult max | Not recommended in ESRD (GFR <15 mL/min/1.73 m²) — d-amphetamine is not dialysable |
Narcolepsy (Adderall IR only)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Narcolepsy — pediatric (6–12 y) | 5 mg PO once daily | Titrate weekly by 5 mg until optimal response | Individualised (range up to 60 mg/day) | Narcolepsy seldom occurs in children <12; first dose on awakening |
| Narcolepsy — ≥12 y and adults | 10 mg PO once daily | Titrate weekly by 10 mg; usual range 5–60 mg/day in divided doses | 60 mg/day (per FDA label range) | Additional doses 4–6 hours apart Modafinil/armodafinil are non-Schedule II alternatives |
Special Populations
- Pediatric <3 years (ADHD): Adderall IR is not recommended in children under 3 years for ADHD. Adderall XR is not approved or studied in children under 6 years. The FDA issued a Drug Safety Communication in June 2025 about increased risk of weight loss with extended-release stimulants in patients younger than 6 years.
- Geriatric (≥65 years): Adderall has not been studied in the geriatric population. When used off-label in older adults, start at the lowest available dose with closer cardiovascular monitoring.
- Renal impairment: Adderall XR requires dose reduction in severe renal impairment (GFR 15 to <30 mL/min/1.73 m²) and is not recommended in ESRD. Renal elimination is highly pH-dependent — alkaline urine substantially reduces excretion and can prolong amphetamine exposure.
- Hepatic impairment: Not formally studied. Because amphetamine is partially hepatically metabolised, hepatic dysfunction has the potential to prolong exposure; use cautiously and consider lower doses.
- Pregnancy: Amphetamines may cause fetal harm (vasoconstriction, decreased placental perfusion, uterine contractions). Available epidemiologic studies have not identified a drug-associated risk of major birth defects or miscarriage. Premature delivery and low birth weight have been reported in mothers dependent on amphetamines. Use only when benefits clearly outweigh risks. National Pregnancy Registry for Psychostimulants: 1-866-961-2388.
- Lactation: Amphetamines are present in human milk at relative infant doses of 2–13.8% of the maternal weight-adjusted dose, with milk-to-plasma ratios of 1.9–7.5. The FDA label specifically advises that breastfeeding is not recommended during treatment with Adderall XR.
The IR tablet covers a school morning or a single work block, then wears off. The XR capsule (10–12 h) covers a school day and into homework time but typically wears off before bedtime, which is generally desirable for sleep. A third extended-release amphetamine product, Mydayis, uses a triple-bead delivery to extend coverage to ~16 hours and is approved for patients ≥13 years — it is useful for adults with very long workdays but has greater insomnia risk if dosed late. Always confirm “dispense as written” on prescriptions: IR generics, brand Adderall, and the XR product are not interchangeable in clinical practice, and pharmacy substitutions are a common cause of perceived loss of efficacy.
Before initiating any amphetamine product, the FDA labelling requires: (1) careful cardiac history including family history of sudden cardiac death or ventricular arrhythmia, plus a physical examination; (2) family history and clinical evaluation for tics or Tourette’s syndrome; (3) screening for risk factors for a manic episode (history of depression, family history of bipolar disorder or suicide); (4) baseline blood pressure, heart rate, height and weight; and (5) assessment of risk for abuse, misuse, and addiction. Document each step in the medical record.
Pharmacology
Mechanism of Action
Amphetamines are non-catecholamine sympathomimetic amines with central nervous system stimulant activity. The FDA label states that the mode of therapeutic action in ADHD is not known. Pharmacologically, amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space — distinguishing them from methylphenidate, which is primarily a reuptake inhibitor without significant releasing activity. Amphetamines also have direct serotonergic activity, which underlies the labelled risk of serotonin syndrome with serotonergic co-administration. Amphetamine inhibits monoamine oxidase to a degree, although the clinical significance of this mechanism in therapeutic dosing is uncertain.
Adderall and Adderall XR contain a fixed combination of four amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate) yielding a 3:1 ratio of d- to l-amphetamine base. The d-isomer is more potent in CNS effects; the l-isomer contributes more to peripheral cardiovascular effects.
Cardiovascular pharmacodynamics: amphetamines produce small mean increases in heart rate (approximately 3–6 bpm) and blood pressure (approximately 2–4 mmHg) at therapeutic doses; some patients show larger increases. Adolescent trial data showed isolated systolic BP elevations ≥15 mmHg in 7% of XR-treated and 11% of placebo-treated patients (4-week trial) — a reminder that BP changes in stimulant trials can be variable and that placebo arms often show similar transient elevations.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IR Tmax ~3 h (both d- and l-amphetamine, fasted); XR Tmax ~7 h; PK is dose-proportional from 10 to 30 mg; food effect on IR not formally studied; PPIs decrease Tmax of amphetamine | IR provides 4–6 h of effect requiring 1–2 daily doses; XR provides 10–12 h of effect with once-daily dosing |
| Distribution | Wide tissue distribution; readily crosses blood-brain barrier; specific Vd not stated in current US PI | Onset of CNS effects within 30–60 minutes of IR administration |
| Metabolism | Hepatic oxidation via CYP2D6 (forms 4-hydroxyamphetamine) and side-chain oxidation pathways; CYP2D6 is genetically polymorphic, leading to population variability in exposure; amphetamine produces minor inhibition of CYP2D6 and (via metabolites) CYP1A2 and CYP3A4 | CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion, quinidine) can increase amphetamine exposure and serotonin syndrome risk; poor metabolisers may have higher exposure at standard doses |
| Elimination | t½ d-amphetamine ~9.8–11 h; t½ l-amphetamine ~11.5–13.8 h; renal excretion is highly pH-dependent (pKa 9.9 — alkaline urine reduces ionisation and renal elimination, acidic urine and high flow rates increase elimination); ~30–40% recovered as unchanged amphetamine and ~50% as alpha-hydroxy metabolites; urinary recovery range 1–75% depending on pH | Urinary alkalinising agents (e.g., sodium bicarbonate) and acidifying agents (e.g., ascorbic acid) significantly alter exposure; severe renal impairment requires dose reduction; hepatic impairment may also prolong exposure |
Formulation duration summary: Adderall IR provides ~4–6 h of clinical effect (single-dose); Adderall XR provides ~10–12 h (single morning dose, dual-bead delivery system); Mydayis (a separate triple-bead amphetamine ER product, ≥13 years) provides ~16 h of coverage but with correspondingly higher insomnia risk.
Side Effects
Mixed amphetamine salts have a recognisable stimulant adverse-effect profile dominated by appetite suppression, insomnia, dry mouth, headache, weight loss, and small cardiovascular changes. Adverse effects tend to be more prominent in adults than in children at therapeutic doses, partly because adults receive higher absolute doses. All quantitative incidence data below are taken directly from the Adderall XR FDA prescribing information clinical trial tables (revised 10/2023).
| Adverse Effect | Population / Incidence | Clinical Note |
|---|---|---|
| Loss of appetite | 22% (children), 36% (adolescents), 33% (adults) vs 2%, 2%, 3% placebo respectively | Most common adverse effect; dose-related; encourage front-loaded breakfast and calorie-dense evening intake |
| Dry mouth | 35% (adults) vs 5% placebo | Especially troublesome in adults; encourage hydration; sugar-free gum or saliva substitutes; dental review for prolonged use |
| Insomnia | 17% (children), 12% (adolescents), 27% (adults) vs 2%, 4%, 13% placebo respectively | Avoid late dosing; switch to shorter-acting product if persistent; assess sleep hygiene |
| Headache | 26% (adults) vs 13% placebo | Often initial and self-limited; ensure hydration; consider taking with food |
| Abdominal pain (children, adolescents) | 14% (children), 11% (adolescents) vs 10%, 2% placebo respectively | Usually mild and transient; take with food |
| Nervousness (adults) | 13% (adults) incidence equal to placebo at 13% in this trial | Often dose-related; consider dose reduction or alternative agent |
| Adverse Effect | Population / Incidence | Clinical Note |
|---|---|---|
| Weight loss | 4% (children), 9% (adolescents), 10% (adults) vs 0%, 0%, 0% placebo respectively | Plot growth at every visit in children; intervene early if percentile crosses downward |
| Emotional lability (children) | 9% (children) vs 2% placebo | Can manifest as irritability, tearfulness, mood swings; consider dose reduction or smoother formulation |
| Vomiting (children) | 7% (children) vs 4% placebo | Take with food; usually transient |
| Anxiety (adults) | 8% (adults) vs 5% placebo | Often dose-related; can lead to discontinuation; consider dose reduction |
| Agitation (adults) | 8% (adults) vs 5% placebo | Dose-related; review for caffeine, decongestants, and other stimulant exposure |
| Nausea | 5% (children), 8% (adults) vs 3% placebo in both | Take with food |
| Nervousness (children, adolescents) | 6% in both vs 2% (children), 6% (adolescents) placebo | Common in pediatric populations; often improves with time |
| Dizziness (adults) | 7% (adults) vs 0% placebo | Caution with driving and machinery until tolerance established |
| Tachycardia (adults) | 6% (adults) vs 3% placebo | Mean HR increase 3–6 bpm; some patients larger; monitor pulse at every visit |
| Diarrhea (adults) | 6% (adults) vs 0% placebo | Generally mild; assess hydration |
| Asthenia / fatigue | 2% (children), 6% (adults) vs 0%, 5% placebo | Often relates to rebound or insufficient sleep; assess timing and dose |
| Fever (children) | 5% (children) vs 2% placebo | Often incidental in pediatric trials; assess for infection |
| Urinary tract infection (adults) | 5% (adults) vs 0% placebo | Reported in pivotal trial; clinical relevance uncertain — likely incidental |
| Increased blood pressure | Mean rise 2–4 mmHg across all CNS stimulants per FDA PI | Some patients have larger increases; routine monitoring captures this early |
| Tics (new onset or worsening) | Reported in trials | Pre-existing tics or family history are warning signs; monitor closely; discontinue if worsening |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Substance use disorder, dependence, overdose, death (boxed warning) | Risk variable; markedly elevated with non-medical use | Any time during therapy; risk rises with high-dose, snorting, IV use | Pre-treatment risk screen; safe storage; monitor throughout treatment; consider gradual taper rather than abrupt stop after prolonged use |
| Sudden death, stroke, myocardial infarction (in patients with serious cardiac disease) | Rare post-marketing reports at therapeutic ADHD doses | Any time; pediatric cases reported in those with structural heart disease | Avoid in known structural cardiac abnormality, cardiomyopathy, serious arrhythmia, or coronary disease; investigate exertional chest pain, syncope, arrhythmia |
| New psychotic or manic symptoms (hallucinations, delusional thinking, mania) | ~0.1% pooled placebo-controlled trials in patients without prior psychotic history | Days to weeks after initiation or dose increase | Consider discontinuation; evaluate for underlying bipolar disorder; do not restart without specialist input |
| Serotonin syndrome (with serotonergic agents or CYP2D6 inhibitors) | Rare but labelled warning (5.8 in current PI) | Hours to days after combining with serotonergic drug or starting CYP2D6 inhibitor | Discontinue both agents immediately; supportive care; this is more prominent for amphetamines than for methylphenidate due to direct serotonergic activity |
| Long-term suppression of growth (pediatric) | Mean weight change −1.1 to −2.8 lbs in first 4 weeks at 10–20 mg XR Higher doses associated with greater early weight loss | Cumulative over months–years; weight changes detectable within 4 weeks | Plot height/weight at every visit; if not tracking expected curve, interrupt treatment or consider drug holidays |
| Seizures | Uncommon labelled — may lower seizure threshold | Any time; risk highest in those with prior seizure history or EEG abnormalities | Discontinue if seizure occurs; use cautiously in patients with seizure disorder; ensure good baseline seizure control |
| Peripheral vasculopathy / Raynaud’s phenomenon | Uncommon post-marketing; can include digital ulceration / soft-tissue breakdown | Any time during treatment; intermittent symptoms | Examine fingers/toes at follow-up; refer to rheumatology if signs of vasculopathy; reduce dose or discontinue if symptomatic |
| Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) | Very rare post-marketing reports | Any time; usually within first weeks of treatment | Immediate discontinuation; emergency dermatology evaluation; permanent contraindication to amphetamines |
| Hypersensitivity (angioedema, anaphylaxis) | Rare | Minutes to days after dosing | Permanent discontinuation; emergency care if airway involved; document allergy |
| Priapism (frequent or prolonged erections) | Rare listed in post-marketing experience | After some time on therapy; may occur during dose changes | Immediate medical attention — irreversible damage possible without prompt urology evaluation |
| Cardiomyopathy (chronic use) | Isolated reports post-marketing, with chronic amphetamine use | Long-term cumulative | Investigate any new exertional symptoms or echocardiographic changes; consider discontinuation |
| Rhabdomyolysis | Rare post-marketing; especially with overdose or strenuous exertion | Acute | Discontinue; emergency care with hydration and CK monitoring |
| Reason for Discontinuation | Incidence (Adults, XR) | Context |
|---|---|---|
| Insomnia | 5.2% | By far the most common adult discontinuation reason — drives formulation timing decisions |
| Anxiety | 2.1% | Often dose-related; consider lower starting dose or methylphenidate alternative |
| Nervousness | 1.6% | Often resolves with dose reduction |
| Dry mouth | 1.6% | Less commonly a discontinuation driver but can be persistent |
| Anorexia | 1.6% | Most common pediatric discontinuation reason (2.9%) |
| Tachycardia | 1.6% | Routine HR monitoring catches this early |
| Headache | 1.6% | Usually self-limited but sometimes persistent |
In pediatric ADHD trials, methylphenidate and amphetamine are broadly similar in tolerability, though amphetamines tend to produce more pronounced appetite suppression and weight loss. In adults, the Adderall XR pivotal trial showed a 12% all-cause discontinuation rate vs ~6% for methylphenidate ER trials — driven mostly by insomnia, anxiety, and dry mouth. A trial of one stimulant class is not a trial of both: approximately 30–40% of patients who have a poor response or tolerability to one class will respond well to the other. Switching classes is a reasonable next step before declaring a stimulant trial unsuccessful.
Drug Interactions
Amphetamines have a significantly more extensive drug-interaction profile than methylphenidate. The current Adderall XR PI Table 4 lists seven categories of clinically important interactions: monoamine oxidase inhibitors, serotonergic drugs, CYP2D6 inhibitors, alkalinising agents, acidifying agents, tricyclic antidepressants, and proton pump inhibitors. Two distinguishing features warrant particular attention: the labelled risk of serotonin syndrome (which is far more prominent in the amphetamine label than in methylphenidate’s), and the pH-dependent renal elimination, which makes routine OTC alkalinisers (e.g., antacids, sodium bicarbonate) and acidifiers (e.g., ascorbic acid) clinically meaningful interactions.
Methylphenidate is metabolised by hydrolytic esterases and avoids CYP-based interactions almost entirely. Amphetamine, in contrast, has partial CYP2D6 metabolism, direct serotonergic activity, and pH-dependent renal excretion. The practical consequence is that patients on amphetamine require closer attention to: (1) any antidepressant change (especially SSRIs, SNRIs, TCAs), (2) any CYP2D6 inhibitor (notably bupropion, paroxetine, fluoxetine), (3) OTC antacids and high-dose vitamin C, and (4) PPI use. For patients with complex polypharmacy, methylphenidate may be the more straightforward stimulant choice.
Monitoring
Monitoring amphetamine therapy is structured around five pillars: cardiovascular vital signs, growth (in children), psychiatric tolerability, abuse/misuse surveillance, and serotonin-related safety when combined with serotonergic medications. The goal is early detection of dose-related side effects and prevention of diversion or misuse.
-
Blood pressure and heart rate
Baseline, then at every dose change and every routine visit (≥3-monthly)
Routine Mean expected rise: BP 2–4 mmHg, HR 3–6 bpm. Sustained BP >130/80 in adults or >95th centile in children, or HR >100 bpm sustained at rest, warrants dose reduction or alternative therapy. -
Height and weight (pediatric)
Every 3–6 months; plot on growth chart
Routine Adolescent trial data showed mean weight loss of −1.1 to −2.8 lbs in the first 4 weeks. Watch for crossing percentiles downward. Consider drug holidays or treatment interruption if growth deviates from expected curve. -
Psychiatric symptom screen
Every visit
Routine Screen for new mania, psychosis, agitation, suicidal ideation, mood lability, and worsening of pre-existing psychiatric conditions. Document family history of bipolar disorder at baseline. -
Abuse and diversion screening
At each refill; PDMP query as required by state
Routine Assess for early refill requests, lost prescriptions, multiple prescriber pattern, and concerning behaviour. Confirm safe storage at home; document patient and family education on diversion risk. Adderall in particular is a frequently diverted “study drug” on college campuses. -
Sleep and appetite
Every visit
Routine Specific questioning about sleep onset latency, total sleep time, and breakfast/evening intake. These data drive dose timing and formulation adjustments. -
Tic/Tourette’s surveillance
Baseline and every visit
Routine New or worsening motor/verbal tics may emerge; assess at each visit; discontinuation considered if clinically significant. -
Serotonin syndrome surveillance
When combined with any serotonergic agent or CYP2D6 inhibitor
Trigger-based Counsel about agitation, hyperthermia, clonus, hyperreflexia, autonomic instability. Initiate amphetamine at a lower dose when adding to existing serotonergic regimen. -
Renal function (XR users)
Annually or as clinically indicated
Routine Adderall XR requires dose reduction in severe renal impairment and is not recommended in ESRD. Re-evaluate eGFR if comorbidities arise. -
Digital examination (Raynaud’s screen)
Baseline, then on patient report
Trigger-based Examine fingers and toes for colour change, ulceration, or coolness. Refer to rheumatology if signs develop. Discontinue or switch agent if vasculopathy progresses. -
ECG / cardiology referral
Only when cardiac risk factors or symptoms identified
Trigger-based Routine baseline ECG is not mandated by FDA labelling but is reasonable when family history suggests inherited arrhythmia (e.g., long QT, HCM) or in symptomatic patients. Investigate exertional chest pain, syncope, or palpitations promptly. -
Treatment continuation review
Annually
Routine Periodically reassess ongoing need for stimulant therapy, particularly in pediatric patients as they mature. Consider planned treatment interruptions or holidays where clinically reasonable.
The single highest-yield monitoring intervention is documenting blood pressure, heart rate, height and weight at every visit, plotted on a growth chart for pediatric patients. Combined with a brief psychiatric, sleep, appetite, and abuse-risk screen, this five-minute review captures the major safety signals — cardiovascular, growth, psychiatric, and substance use — that the FDA boxed warning and labelled precautions all centre on.
Contraindications & Cautions
Absolute Contraindications
- Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or use within 14 days of MAOI discontinuation — this includes the antibiotic linezolid and intravenous methylene blue. Risk of hypertensive crisis, stroke, MI, aortic dissection, and death.
- Known hypersensitivity to amphetamine or any product component — including prior anaphylaxis, angioedema, severe cutaneous reaction, or Stevens-Johnson syndrome.
Relative Contraindications (Specialist Input Recommended)
- Known structural cardiac abnormalities (e.g., hypertrophic cardiomyopathy), cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease — sudden death has been reported at therapeutic ADHD doses; cardiology assessment required before any consideration of use.
- Active or recent substance use disorder — amphetamine has very high abuse potential. Use only under specialist supervision with close monitoring; non-stimulant alternatives (atomoxetine, viloxazine, guanfacine ER, clonidine ER) should be considered first.
- Pre-existing psychotic disorder — symptoms may be exacerbated; co-management with psychiatry essential.
- Bipolar disorder, especially without mood stabiliser cover — risk of mania induction; do not initiate without psychiatric input and adequate mood stabilisation.
- Pregnancy — amphetamines may cause fetal harm via vasoconstriction and uterine contractions, with reported risks of premature delivery and low birth weight in dependent mothers; epidemiologic studies have not identified a clear teratogenic risk. Use only when benefits clearly outweigh risks; encourage National Pregnancy Registry for Psychostimulants enrolment (1-866-961-2388).
- Lactation — the FDA label specifically advises against breastfeeding during Adderall XR therapy. RID 2–13.8% of maternal weight-adjusted dose.
- End-stage renal disease (ESRD, GFR <15 mL/min/1.73 m²) — Adderall XR is not recommended; d-amphetamine is not dialysable.
- Pre-existing peripheral vasculopathy or Raynaud’s phenomenon with ischaemic complications — risk of digital ulceration; specialist input recommended before initiation.
Use with Caution
- Pre-existing hypertension or tachyarrhythmia — small but real BP and HR increases; ensure stable control before initiation; monitor closely.
- History of motor or verbal tics, or family history of Tourette’s syndrome — may emerge or worsen; assess at every visit.
- History of seizure disorder or EEG abnormalities — amphetamines may lower the seizure threshold; ensure good baseline seizure control before initiation; discontinue if seizure occurs.
- Concurrent use of serotonergic medications or CYP2D6 inhibitors — increased risk of serotonin syndrome; initiate at lower doses with monitoring.
- Severe renal impairment — dose reduction required for Adderall XR.
- Concurrent acidifying or alkalinising agents — may significantly alter amphetamine exposure; counsel about OTC antacids and high-dose vitamin C.
- Pediatric patients on year-round stimulant therapy — monitor growth; consider drug holidays.
- Older adults (≥65 years) — limited safety data; cardiovascular comorbidity is more common; start at the lowest available dose.
- Patients with depression, anxiety, or suicidal ideation — mood worsening or new psychiatric symptoms have been reported; close monitoring and integrated mental health management required.
Adderall and Adderall XR have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including amphetamines, can result in overdose and death. Risk is increased with higher doses or with unapproved methods of administration such as snorting or injection. (Boxed warning revised 10/2023 across the amphetamine and methylphenidate stimulant class.)
Pre-treatment: Assess each patient’s individual risk for abuse, misuse, and addiction before prescribing. Educate patients and their families about these risks, the importance of safe (preferably locked) storage, and proper disposal of unused medication.
During treatment: Reassess each patient’s risk at each visit and frequently monitor for signs and symptoms of abuse, misuse, and addiction. Maintain careful prescription records and check the state Prescription Drug Monitoring Program where available. Counsel patients explicitly: never share medication, never alter the route of administration, and never increase the dose without prescriber agreement.
Discontinuation: Amphetamines may produce physical dependence after prolonged use. Withdrawal symptoms can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor changes. Consider gradual taper rather than abrupt cessation after long-term use.
Patient Counselling
Purpose of Therapy
Adderall and Adderall XR are stimulant medicines used to treat attention-deficit/hyperactivity disorder (ADHD); the immediate-release Adderall is also used for the sleep disorder narcolepsy. In ADHD, these medicines can help improve attention, reduce impulsivity, and reduce hyperactivity. Adderall works best when combined with non-medication strategies — for ADHD, that means behavioural strategies, school or workplace accommodations, sleep hygiene, exercise, and (where appropriate) parent or family training. The medicine is not a cure for ADHD; it manages symptoms while it is in your system.
How to Take
Adderall (immediate-release) tablets are usually taken 1–2 times a day, with the first dose on awakening. Adderall XR capsules are taken once daily in the morning. The XR capsule may be swallowed whole or opened and the contents sprinkled on a small amount of applesauce — the applesauce should be eaten right away without chewing the beads, and you should not take less than a full capsule. Adderall can be taken with or without food. To avoid trouble sleeping, do not take any short-acting dose late in the afternoon or evening, and do not take XR after the morning.
Sources
- U.S. Food and Drug Administration. ADDERALL XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII — Prescribing Information. Takeda Pharmaceuticals. Revised October 2023. Reference ID 5260286. accessdata.fda.gov Most recent FDA-approved label for Adderall XR; source of all quantitative adverse-event incidence data, the seven-category drug interaction Table 4, dosing recommendations, and labelled warnings used in this monograph.
- U.S. Food and Drug Administration. ADDERALL (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets), CII — Prescribing Information. Teva Pharmaceuticals. Revised October 2023. Reference ID 5260137. accessdata.fda.gov Current FDA-approved label for immediate-release Adderall; source of narcolepsy dosing information, ADHD pediatric dosing for ages 3–5, and the more comprehensive drug interaction listing.
- U.S. Food and Drug Administration. Drug Safety Communication: Risk of weight loss in children younger than 6 years taking extended-release stimulants for ADHD. June 30, 2025. fda.gov Recent FDA safety communication informing labelling updates for all extended-release stimulants regarding weight loss in patients younger than 6 years.
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi: 10.1016/S2215-0366(18)30269-4 Network meta-analysis comparing ADHD medications across age groups; methylphenidate is favoured in children/adolescents while amphetamines are favoured in adults on the efficacy/tolerability balance.
- The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–1086. doi: 10.1001/archpsyc.56.12.1073 Landmark NIMH Multimodal Treatment of ADHD (MTA) study — although it primarily evaluated methylphenidate, it remains the foundational trial supporting medication management of ADHD in school-aged children.
- Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904. doi: 10.1056/NEJMoa1110212 Large cohort study (~1.2 million patients) showing no significant increase in serious cardiovascular events with stimulant ADHD medications including amphetamines; supports the labelled “avoid in serious cardiac disease” framing rather than a population-wide cardiac restriction.
- Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;8(8):CD007813. doi: 10.1002/14651858.CD007813.pub3 Cochrane systematic review on amphetamines specifically for adult ADHD — found short-term efficacy with low to very low certainty of evidence and notable rates of adverse events.
- Wolraich ML, Hagan JF Jr, Allan C, et al; Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. doi: 10.1542/peds.2019-2528 American Academy of Pediatrics guideline; supports stimulants (methylphenidate or amphetamines) as first-line pharmacotherapy for ADHD in children ≥6 years.
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. nice.org.uk/guidance/ng87 UK national guideline; positions methylphenidate as the first-line stimulant in children and lisdexamfetamine or methylphenidate as first-line stimulant options in adults — mixed amphetamine salts are an alternative within the amphetamine class.
- American Academy of Sleep Medicine. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893. doi: 10.5664/jcsm.9328 AASM guidance covering pharmacological management of narcolepsy; modafinil and armodafinil are typically preferred first-line wake-promoting agents over amphetamines.
- Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present — a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479–496. doi: 10.1177/0269881113482532 Comprehensive review of amphetamine pharmacology, including its dual reuptake-inhibitor and monoamine-releaser mechanism that distinguishes it from methylphenidate.
- Volkow ND, Wang G-J, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084–1091. doi: 10.1001/jama.2009.1308 PET imaging evidence linking ADHD to deficits in dopamine reward pathways relevant to the therapeutic action of stimulant medications including amphetamines.
- Huybrechts KF, Bröms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations. JAMA Psychiatry. 2018;75(2):167–175. doi: 10.1001/jamapsychiatry.2017.3644 Large multinational cohort study evaluating birth defect risk with stimulant exposure during pregnancy — informs the current pregnancy risk discussion in counselling.
- Pottegård A, Bjerregaard BK, Glerup S, et al. Use of ADHD medication during pregnancy: a Scandinavian register-based cohort study. Br J Clin Pharmacol. 2014;78(5):1136–1142. doi: 10.1111/bcp.12428 Register-based pregnancy outcomes study informing the current understanding of premature delivery and low birth weight risks with maternal stimulant use.